TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10523963
Drug: Deoxinate therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deoxinate therapy
Study: 7263143
Drug: CogentinTM (benztropine
Approvals — FDA: no, EMA: no, PMDA: no
Description: CogentinTM (benztropine mesylate) at increasing doses (maximum 2 mg)
Study: 30989965
Drug: Bushen Huoxue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bushen Huoxue Anshen Fang (Traditional Chinese Medicine)
Study: 28980140
Drug: Dexamethasone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (10 mg) and paracetamol (1000 mg)
Study: 28980140
Drug: Dexamethasone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (10 mg) alone
Study: 15222836
Drug: Preparing for
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparing for the Drug Free Years program
Study: 2750998
Drug: Acetazolamide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (1 g, intravenous)
Study: 24172719
Drug: Cola matched
Normalized name: cola extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cola matched for caffeine and CHO (CC)
Study: 19446864
Drug: Aspirin 81
Normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin 81 mg with 400 mg phytosterols
Study: 19446864
Drug: Non-enteric coated
Normalized name: diclofenac sodium (enteric coated core) 50 MG / miSOPROStol (non-enteric coated mantle) 200 MCG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-enteric coated aspirin 81 mg
Study: 1938514
Drug: Low-dose total
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose total body irradiation (TBI)
Study: 1938514
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (CHVmP)
Study: 6110090
Drug: 2400 rad
Normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2400 rad craniospinal radiation therapy (RT)
Study: 6110090
Drug: 1800 rad
Normalized name: RAD-IFN
DrugBank: Nadofaragene firadenovec (DB17381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1800 rad craniospinal radiation therapy (RT)
Study: 26930603
Drug: Creatine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine supplementation (0.3 g/kg)
Study: 23161047
Drug: Topical latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical latanoprost 0.005% (LP)
Study: 18842999
Drug: Red clover-derived
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red clover-derived isoflavones (84 mg/d)
Study: 11134564
Drug: Lower-dose platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower-dose platelet transfusions (38% reduction in mean platelet dose)
Study: 1488937
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose of alcohol (.75 ml/kg)
Study: 1488937
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of alcohol (.33 ml/kg)
Study: 3099267
Drug: Intraglobulin (Biotest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraglobulin (Biotest Pharma, West Germany), 120 mg/kg intravenously, within 2 to 4 hours of delivery (Group A)
Study: 3099267
Drug: Intraglobulin (Biotest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraglobulin (Biotest Pharma, West Germany), 120 mg/kg intravenously, on days 1 and 8 (Group B)
Study: 27150393
Drug: 20% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% glucose intravenous infusion
Study: 27150393
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline intravenous infusion (control)
Study: 25663170
Drug: L-Dopa carbidopa
Normalized name: carbidopa / levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Dopa carbidopa 100 mg
Study: 25663170
Drug: Pramipexole 1.5
Normalized name: pramipexole 1.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole 1.5 mg (150 mg LED)
Study: 17960793
Drug: High-dose calcitriol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose calcitriol (DN-101; 45 mug) plus docetaxel (36 mg/m2)
Study: 17960793
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus docetaxel (36 mg/m2)
Study: 16504428
Drug: Oral continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral continuous combined hormone therapy (conjugated equine oestrogens 0.625 mg/d plus medroxyprogesterone acetate 2.5 mg/d or 5 mg/d)
Study: 14583107
Drug: Standard advanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard advanced cardiac life support (ACLS) intervention and empiric early administration of bicarbonate
Study: 10892762
Drug: GAD antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD antibodies in SMS patients
Study: 10892762
Drug: GAD antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD antibodies in T1DM patients
Study: 1396839
Drug: Nitroglycerin patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin patches (mean necessary effective patch dose: 125 cm2)
Study: 1396839
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) capsules (administered q5h)
Study: 1396839
Drug: Placebo patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patches and capsules
Study: 30561539
Drug: GMZ2 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMZ2 vaccine (30 or 100 µg formulated in CAF01 or 100 µg formulated in Alhydrogel)
Study: 30561539
Drug: GMZ2-Alhydrogel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMZ2-Alhydrogel (100 µg)
Study: 30561539
Drug: Baseline vaccine-specific
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline vaccine-specific antibody concentrations
Study: 25763862
Drug: Golimumab 50
Normalized name: GOLIMUMAB 50MG/0.5ML INJ SYRINGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golimumab 50 mg and 100 mg
Study: 20858034
Drug: Lidocaine gel
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine gel combined with ketamine (100 mg)
Study: 20858034
Drug: Lidocaine gel
Normalized name: LIDOCAINE 4 g in 100 g EXTRACORPOREAL PATCH [Arthcal 4% Lidocaine Gel Patches]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine gel combined with normal saline
Study: 15053030
Drug: Individual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual therapy on request (comparison condition)
Study: 12195844
Drug: Nebulised fluticasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised fluticasone propionate (FP) 2 x 0.5 mg/2 ml bd
Study: 12195844
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone 2 mg/kg/day for 4 days followed by 1 mg/kg/day for 3 days (maximum 40 mg then 20 mg)
Study: 9696374
Drug: Intrathecal mafosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal mafosfamide at a dose of 20 mg once or twice weekly until remission, followed by weekly administrations for consolidation and every 3 to 4 weeks for maintenance
Study: 8596759
Drug: Oral isosorbide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral isosorbide dinitrate (ISDN) 10 or 20 mg
Study: 2520814
Drug: Flurbiprofen (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (100 mg, twice daily)
Study: 2520814
Drug: Naproxen-sodium (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen-sodium (500 mg, twice daily)
Study: 1155823
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Theophylline and Ephedrine
Study: 27129908
Drug: Anterior-inferior tibiofibular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior-inferior tibiofibular ligament (AITFL) anatomical repair with augmentation
Study: 11474002
Drug: virologic nonresponders
Approvals — FDA: no, EMA: no, PMDA: no
Description: virologic nonresponders (both treatments)
Study: 9710889
Drug: Anti-tumor necrosis
Normalized name: G 1 (anti-tumor agent)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-tumor necrosis factor-α monoclonal antibody therapy
Study: 28063515
Drug: ω‐3 supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω‐3 supplementation (3 g/d of fish oil containing 37% eicosapentaenoic acid and 23% docosahexaenoic acid)
Study: 28063515
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 g/d of sunflower oil containing 65% linoleic acid)
Study: 23967126
Drug: trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: trivalent inactivated influenza vaccine
Study: 19118379
Drug: Ritonavir 100
Normalized name: ritonavir 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir 100 mg once daily
Study: 19118379
Drug: Ritonavir 100
Normalized name: ritonavir 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir 100 mg twice daily
Study: 9988796
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (50 g/day)
Study: 6168363
Drug: Bleomycin-radiotherapy protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bleomycin-radiotherapy protocol (15 mg bleomycin I.V. on alternate days followed by radiation)
Study: 21904964
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy targeting a blood glucose level between 4.4 and 6.1 mmol/l (n = 125)
Study: 21904964
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin therapy targeting a blood glucose level less than 11.0 mmol/l (n = 123)
Study: 14712285
Drug: Horse antithymocyte
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horse antithymocyte globulin 15 mg/kg/day for 5 days
Study: 14712285
Drug: Rabbit antithymocyte
Normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabbit antithymocyte globulin 3.75 mg/kg/day for 5 days
Study: 9446334
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (chemotherapy and radiotherapy) for advanced rectal cancer (T3N1M0 or T4N2M1) and localized large bowel cancer (G2 and G3 grading)
Study: 29605500
Drug: Chemotherapy treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy treatment (N=98)
Study: 26956698
Drug: Sofosbuvir (SOF)
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir (SOF) 400 mg and Velpatasvir (VEL) 100 mg for 12 weeks
Study: 25694008
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity extracorporeal shockwave therapy (LI-ESWT)
Study: 25694008
Drug: Placebo/sham therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo/sham therapy
Study: 21672334
Drug: 70 mg
Normalized name: silybin 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg alendronate once every 2 weeks plus 0.5 μg alfacalcidol daily
Study: 21672334
Drug: alfacalcidol 0.5
Normalized name: alfacalcidol 0.5 MCG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfacalcidol 0.5 μg daily alone
Study: 16394086
Drug: 15% glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15% glucose (200 mg/m2.min)
Study: 16394086
Drug: saline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline (50 ml/h)
Study: 31786652
Drug: Random forest
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random forest model based on pre-treatment ADC image-derived radiomics features
Study: 18676227
Drug: Fusidic acid
Normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fusidic acid (1 g)
Study: 18676227
Drug: Cefepime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime (2 g)
Study: 16822633
Drug: Azithromycin formulation
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin formulation 1
Study: 16822633
Drug: Azithromycin formulation
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin formulation 2
Study: 12838698
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of Oratest
Study: 10393397
Drug: Bolus enalaprilat
Normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bolus enalaprilat (0.004 mg/kg)
Study: 10393397
Drug: Continuous enalaprilat
Normalized name: Enalaprilat
DrugBank: Enalaprilat (DB09477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous enalaprilat infusion (0.004 mg/kg)
Study: 26459006
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (conventional medication and physical therapy)
Study: 18719941
Drug: OXXEL (oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: OXXEL (oxaliplatin 100 mg/m² i.v. on day 1, capecitabine 1,000 mg/m² orally twice daily from day 1 to day 11)
Study: 18719941
Drug: OXAFAFU (oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: OXAFAFU (oxaliplatin 85 mg/m² i.v. on day 1; 6S‐leucovorin 250 mg/m² i.v. and fluorouracil 850 mg/m² i.v. on day 2)
Study: 15488877
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg combined with Ramipril 10 mg
Study: 3422243
Drug: 0.001 molar
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.001 molar solution of quinine hydrochloride (placebo rinse)
Study: 16525097
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg twice a day for 3 days) + Quinine (30 mg/kg/day divided every 8 hours for 3 days)
Study: 16525097
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg twice a day for 5 days) + Quinine (30 mg/kg/day divided every 8 hours for 3 days)
Study: 16525097
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg three times a day for 3 days) + Quinine (30 mg/kg/day divided every 8 hours for 3 days)
Study: 16525097
Drug: Quinine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine (30 mg/kg/day divided every 8 hours for 3 days) + Doxycycline (100 mg twice a day for 7 days)
Study: 14571236
Drug: Palivizumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palivizumab (15 mg/kg, intramuscularly, 5 monthly injections)
Study: 11314410
Drug: Ferric sulfate
Normalized name: Ferric Sulfate
DrugBank: Ferric sodium citrate (DB13771)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferric sulfate 15.5% solution (applied for 15 seconds)
Study: 11314410
Drug: Formocresol solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formocresol solution (five minute procedure of Buckley's formula)
Study: 8994331
Drug: Parkryl (Mei-Shih),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parkryl (Mei-Shih), 10 mg per day as an adjunct to Madopar
Study: 8994331
Drug: Jumexal (Labatec),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jumexal (Labatec), 10 mg per day as an adjunct to Madopar
Study: 6546806
Drug: Pirenzepine, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine, 50 mg twice daily
Study: 6546806
Drug: Benzilonium bromide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzilonium bromide, 17.5 mg twice daily
Study: 6546806
Drug: Benzilonium bromide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzilonium bromide, 35 mg twice daily
Study: 6546806
Drug: Benzilonium bromide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzilonium bromide, 70 mg twice daily
Study: 31026738
Drug: Brazil nut
Normalized name: Brazil nut
DrugBank: Brazil nut (DB10510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brazil nut group (BN), consumed 1 unit/d of Brazil nuts (∼ 1261 μg/Se) for 2 months.
Study: 22498739
Drug: CTDa (attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTDa (attenuated oral CTD)
Study: 18539106
Drug: Denosumab every
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab every 3 months (Q3M; 6, 14, or 30 mg) or every 6 months (Q6M; 14, 60, 100, or 210 mg)
Study: 18539106
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of denosumab
Study: 18539106
Drug: Retreatment with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retreatment with denosumab (60 mg Q6M)
Study: 18539106
Drug: Open-label oral
Normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label oral alendronate weekly
Study: 10557173
Drug: Intra-articular irrigation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular irrigation injection therapy
Study: 10557173
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of steroid (Control)
Study: 8687089
Drug: Cefuroxime prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime prophylaxis (3 g intravenous dose during induction of anaesthesia)
Study: 2104681
Drug: Cholecystokinin-octapeptide (CCK-OP)
Normalized name: Cholecystokinin C-terminal octapeptide
DrugBank: Sincalide (DB09142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cholecystokinin-octapeptide (CCK-OP) 50 nanograms per kilogram intravenously over a ten minute period daily
Study: 2104681
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (placebo) intravenously
Study: 27058204
Drug: Early rehabilitation
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early rehabilitation and mobilization in addition to standard treatment
Study: 24094019
Drug: Elastic ligatures
Normalized name: elastin
DrugBank: Elastin (human) (DB15364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elastic ligatures aged in the oral environment for 4 weeks
Study: 24094019
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group of elastic ligatures not subjected to oral degradation
Study: 18450878
Drug: Observation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation therapy without prescription
Study: 18450878
Drug: Observation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation therapy with prescription
Study: 11574363
Drug: rapacuronium 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: rapacuronium 1.2 mg/kg
Study: 11574363
Drug: rapacuronium 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: rapacuronium 1.0 mg/kg
Study: 11574363
Drug: rocuronium 0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: rocuronium 0.50 mg/kg
Study: 11574363
Drug: saline 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: saline 0.05 mL/kg
Study: 3354808
Drug: bupivacaine 30
Normalized name: BUPivacaine 300 MG / meloxicam 9 MG in 10.5 ML Extended Release Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 30 mg plus buprenorphine 0.03 mg (group B, n = 30)
Study: 3354808
Drug: bupivacaine 30
Normalized name: BUPivacaine 300 MG / meloxicam 9 MG in 10.5 ML Extended Release Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 30 mg plus buprenorphine 0.045 mg (group C, n = 30)
Study: 3354808
Drug: bupivacaine 30
Normalized name: BUPivacaine 300 MG / meloxicam 9 MG in 10.5 ML Extended Release Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 30 mg (group A, n = 30)
Study: 8445413
Drug: Active specific
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active specific immunotherapy (ASI) with autologous tumor cell-BCG vaccine
Study: 8445413
Drug: Active specific
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active specific immunotherapy (ASI)
Study: 354840
Drug: Benzopyranoperidine 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzopyranoperidine 2 mg
Study: 354840
Drug: Benzopyranoperidine 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzopyranoperidine 4 mg
Study: 354840
Drug: Codeine sulfate
Normalized name: Codeine Sulfate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine sulfate 120 mg
Study: 24352875
Drug: CHELT (Cold
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHELT (Cold air and High Energy Laser Therapy)
Study: 24352875
Drug: ESWT (Extracorporeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESWT (Extracorporeal Shock Waves Therapy)
Study: 22999730
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise training (ET) at 60% of peak oxygen consumption, 2 times weekly for 10 years.
Study: 19443681
Drug: Etoricoxib 120
Normalized name: etoricoxib 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 120 mg once daily with triphasic oral contraceptive (OC)
Study: 19443681
Drug: Etoricoxib 60
Normalized name: etoricoxib 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 60 mg once daily with triphasic oral contraceptive (OC)
Study: 19443681
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with triphasic oral contraceptive (OC)
Study: 19443681
Drug: Etoricoxib (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib (both dosages) with triphasic oral contraceptive (OC)
Study: 17302652
Drug: Comprehensive vision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive vision and eye examinations with subsequent treatment (new eyeglasses, referrals for occupational therapy, glaucoma management, cataract surgery)
Study: 17302652
Drug: Comprehensive vision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive vision and eye examinations with subsequent treatment
Study: 15346658
Drug: Transdermal 17beta‐estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17beta‐estradiol 0.05 mg/day